Oliver Engert Acquires 2,660 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 2,660 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the acquisition, the insider owned 63,898 shares in the company, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Wednesday, September 2nd, Oliver Engert bought 2,458 shares of Enovis stock. The stock was bought at an average price of $20.32 per share, for a total transaction of $49,946.56.
• On Thursday, September 3rd, Oliver Engert bought 5,140 shares of Enovis stock. The shares were bought at an average cost of $19.46 per share, for a total transaction of $100,024.40.
• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average price of $20.92 per share, with a total value of $20,920.00.
• On Thursday, June 11th, Oliver Engert purchased 1,200 shares of Enovis stock. The stock was bought at an average cost of $21.62 per share, with a total value of $25,944.00.
• On Wednesday, June 10th, Oliver Engert acquired 1,000 shares of Enovis stock. The stock was bought at an average price of $23.00 per share, for a total transaction of $23,000.00.

Enovis Trading Down 4.5%

Enovis stock opened at $19.07 on Thursday. The firm has a market cap of $1.10 billion, a PE ratio of -0.99 and a beta of 1.31. Enovis Corporation has a 12 month low of $18.52 and a 12 month high of $34.28. The stock’s 50 day simple moving average is $25.40 and its two-hundred day simple moving average is $24.16. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The firm had revenue of $582.78 million during the quarter, compared to analyst estimates of $581.84 million. During the same period in the previous year, the firm earned $0.79 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Analysts anticipate that Enovis Corporation will post 3.15 earnings per share for the current year.

Institutional Trading of Enovis

Several institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC increased its stake in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Enovis by 37.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock valued at $10,226,000 after buying an additional 73,116 shares in the last quarter. Empowered Funds LLC lifted its stake in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after buying an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. Finally, Amundi boosted its holdings in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after buying an additional 9,762 shares during the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ENOV. Citigroup reiterated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. UBS Group restated a “buy” rating and issued a $51.00 price target (up from $50.00) on shares of Enovis in a research note on Tuesday, July 28th. Canaccord Genuity Group reduced their price target on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a report on Monday, August 17th. Zacks Research upgraded Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. Finally, Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.38.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.